

Original Research Article

Body mass index and clinical outcomes in Egyptian women with breast cancer: a multi-institutional study

ABSTRACT

Purpose: The aim of this work was to evaluate the association between body mass index (BMI) and clinical outcomes among Egyptian female breast cancer patients.

Methods: We reviewed the file registry of 629 patients with operable breast cancer regarding age, sex, height, weight, menopausal status, family history of breast cancer, tumor features, TNM arrangement, and treatment during the period from January 2006 to December 2012. In our studies, obesity was defined as a BMI of ≥ 30 kg/m². The primary objective was to estimate the effect of body mass index on the clinical outcomes of breast cancer patients including DFS and OAS.

Results: A total of 629 patients with a mean age of 51.1 years. Stage III and Stage II presented 52% and 46.6% respectively. Overweight and obese patients represent 60.5% of all patient population. there was no association between tumor stage, grade or menopausal status and BMI. Patients with normal BMI showed a median survival of 95.3 months [CI: 54.6,136.06]. This was significantly higher than overweight and obese patients ($p = 0.001$). Nearly one-third of patients (29.1%) with normal BMI experienced disease relapse compared to 32.8% for overweight and obese patients, however, this was statistically not significant (0.097).

Conclusion: According to the results of this retrospective study, increased BMI may be associated with less favorable prognosis of breast cancer patients.

INTRODUCTION

Breast cancer is one of the most frequent cancers and is considered a chief reason of cancer mortality among females worldwide. It accounts for 25% of all cancer cases and 15% of all cancer deaths among females (1). In Egypt; Breast Cancer is estimated to be the most common female cancer with a crude incidence rate of 35.8 per 100,000 (2).

The prevalence of obesity being overweight is defined by a high body mass index (BMI), which has been increasing regardless of sex, age or whether people live in developed or developing countries (3, 4).

According to a study published in the lancet, Egypt is the seventh most overweight country in the world (5). Obesity may increase the incidence of various human cancers, as reported in several epidemiological studies (6-9).

It is known that obesity is linked with increased cancer risk for several types of cancers, including breast cancer. This increased risk may be attributed to the elevation of different hormones like estrogen and insulin (1, 10).

Estrogen is mainly produced in woman's ovaries in early life, but after menopause, the fat becomes the main source of estrogen, and so in obese ladies, estrogen markedly increase in relation to those with normal BMI due to fat itself and lower levels of sex hormone-binding globulin that increase estrogen in the body (11).

Obesity has a worse prognostic factor in patients with breast cancer in several studies although the results were different among all studies due to the presence of different factors like BMI cut-offs, the extent of disease, estrogen receptor status, menopausal status, mode of treatments (12-16).

Up to our knowledge, there are no studies investigating the association between body mass index (BMI) and breast cancer outcomes among Egyptian breast cancer ladies. The aim of this work was to evaluate the association between BMI and breast cancer outcomes for patients in Egypt.

PATIENTS AND METHODS

Patients and data collection

Review of our file registry of the patient's with operable breast cancer who attended to Clinical Oncology Department, Minia University and Clinical Oncology & Nuclear Medicine Department, Mansoura University and were analyzed during the period from January 2006 to

December 2012. The two hospitals were able to provide standardized methods in pathological diagnosis, surgery, chemotherapy, radiotherapy, and follow-up care for breast cancer patients. This study includes a cohort of 629 patients with their recorded height and weight in the database. Age, sex, height and weight, family history of breast cancer, menopausal status, tumor characteristics, TNM classification, and treatment (chemotherapy, endocrine therapy, and radiation therapy) were reviewed in patient's records. The TNM classification and histological classification were registered according to the UICC staging (17) and WHO classification systems, (18) respectively. The study was reviewed and approved by the Institutional Review Board (IRB) at the faculty of medicine. Information on ER/PR/HER2 was also taken. If at least 1% of nuclei in the tumor were immunohistochemically positive for ER or PR, it was considered positive. An immunohistochemical HER2 score of 3+ and/or a positive FISH result was defined as overexpression.

Statistical considerations

According to the recommendations of the World Health Organization (WHO), body mass index was calculated as weight divided by the square of height (kg/m^2), and can be classified in 5 BMI subgroups: underweight $<18.5 \text{ kg}/\text{m}^2$; normal $18.5\text{--}24.9 \text{ kg}/\text{m}^2$; overweight $25.0\text{--}29.9 \text{ kg}/\text{m}^2$; obesity $30.0\text{--}34.9 \text{ kg}/\text{m}^2$; and excess obesity $\geq 35 \text{ kg}/\text{m}^2$. In our analyses, obesity was defined as a BMI of $\geq 30 \text{ kg}/\text{m}^2$. DFS was calculated from the end of adjuvant chemotherapy to the first date of a local, regional, or distant relapse; of the diagnosis of second primary cancer, including contralateral invasive breast cancer; or of death from any cause.

Kaplan – Meier methods were used to estimate survival curves. Overall survival was calculated from the date of the end of adjuvant chemotherapy to the date of death from any cause. All reported P values are two-sided, and $P < 0.05$ was considered statistically significant, it was done by using SPSS version 20.

RESULT

Patient Characteristics

Table (1) illustrates patient characteristics. A total of 629 patients included in our study with a mean age of 51.1 years. Stage III and Stage II presented 52% and 46.6% respectively. Half of the cases were postmenopausal at the time of diagnosis (52.7%). ER and PR positive tumors represented 45.8% and 46% respectively. Overweight and obese patients represent 60.5% of all patient population compared to 36% and 3.5% for those with normal and underweight patients respectively.

Clinical features of breast carcinoma in relation to BMI

Patients with advanced breast cancer tumor stage composed half of all patients in our study (52%), of them those with high BMI were 62.1% (204/328) however the association between BMI and advanced tumor stage was not statistically significant [$p = 0.443$]. Similarly, Stage II represented 46.6% of our cohort. Of them, those with high BMI composed 58.3% (171/293) however, this was statistically not significant. Overweight and obesity were more prevalent in postmenopausal women (57.6%) compared to 40.7% for premenopausal women but this was not statistically significant ($p = 0.196$). Similarly, there was no association between tumor grade and BMI ($p = 0.486$). Data were available regarding estrogen receptor status in nearly two thirds (65.8%) of patients (414/629). Overweight and obese patients composed 61% of all ER-positive tumors however this was not associated with BMI ($p = 0.941$). About two-thirds of our study population (70.4%) have positive progesterone receptors. Obese and overweight patients presented a majority (61.3 %) of this population however the association between BMI and positive hormonal status was not proved to be significant ($p = 0.877$).

Correlation between BMI and Survival

Regarding survival, there was 70% of breast cancer patients with normal BMI alive at the time of analysis. This compared to 58% were alive for overweight and obese patients. In fact, patients with normal BMI showed a median survival of 95.3 months [CI: 54.6,136.06]. This was significantly higher than overweight and obese patients ($p = 0.001$). Nearly one-third of patients (29.1%) with normal BMI experienced disease relapse compared to 32.8% for overweight and obese patients, however, this was statistically not significant (0.097).

Discussion

There are contradictory results about the role of obesity in the development of cancer. In some studies, high BMI is considered as a risk factor for breast cancer development and increased mortality (20-28). On the other hand, other studies have reported that increased BMI may also be protective of mortality (29-33). So according to these ambiguous results, the rank of BMI as a prognostic element for breast Cancer continued undefined. Our results are in the same line of the concept that BMI is an independent prognostic tool in breast cancer patients. BMI as a general independent factor does not have a significant influence on DFS but does have a significant effect on OS, with overweight and obese patients (heavier) patients showing worse survival. As shown in our result in which; Overweight and Obese patients had a bad consequence compared to normal and underweight patients as regard overall survival, patients with normal BMI showed a mean survival of 109 months and a median survival of 95.3 months. This was significantly higher than overweight and obese patients ($p = 0.001$), but no difference was seen in DFS. These results are consistent with prior studies that have exhibited a poorer OS with increasing weight (34) or BMI (22, 35). Poorer DFS percentages were also noticed in some studies (36). Other studies did not explore an impact of obesity on OS or DFS (37). while another study finds an effect of obesity on both OS or DFS (38). In our study, there were no positive correlations between BMI and tumor features such as tumor stage, hormonal receptor and tumor grade These findings are inconsistent with earlier studies (22, 36, 39, 40) that shown a robust correlation between obesity and tumor size as in those trials most of the patients with obese BMI had tumors of ≥ 2 cm diameter compared to patients with normal BMI, this may be related to relatively small number of our patients

Limitations

However, the data in the retrospective studies are almost always incomplete and accused of selection bias because it depends mainly on medical documentation. But, in reality, it reflects real-life oncologists' experience. Other limitations of our study are like a lack of data gathering on weight changes at the termination of adjuvant chemotherapy or during follow-up was not done; and the reporting of unplanned subgroup analysis. Also, the small sample size is an important limitation.

Conclusion & Recommendations

In conclusion, this retrospective study reveals that BMI is an independent prognostic factor for OS in patients with operable breast cancer. Our study supports the indication that obese BMI denotes a poor risk factor for the consequence. With increasing obesity universal, more studies on alleviating the treatment of obese BC patients are required.

Statement of Ethics

The institutional review board of each participating center approved this multicenter retrospective study, and written informed consent was waived because of the retrospective design.

Compliance with ethical standards

Ethical approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Retrospective review of de-identified patients using the Cancer Registry database in both Minia And Mansura University.

References

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. *CA: A Cancer Journal for Clinicians*. 2015;65(2):87-108.
2. Ibrahim AS, Khaled HM, Mikhail NN, Baraka H, Kamel H. Cancer incidence in Egypt: results of the national population-based cancer registry program. *Journal of cancer epidemiology*. 2014;2014:437971.
3. Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. *BMJ*. 2007;335(7630):1134.
4. Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. *The lancet*. 2014;384(9945):766-81.
5. Bianchini F, Kaaks R, Vainio H. Overweight, obesity, and cancer risk. *The lancet oncology*. 2002;3(9):565-74.

6. Ursin G, Longnecker MP, Haile RW, Greenland S. A meta-analysis of body mass index and risk of premenopausal breast cancer. 1995.
7. Van den Brandt PA, Spiegelman D, Yaun S-S, Adami H-O, Beeson L, Folsom AR, et al. Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. *American journal of epidemiology*. 2000;152(6):514-27.
8. MacInnis RJ, English DR. Body size and composition and prostate cancer risk: a systematic review and meta-regression analysis. *Cancer causes & control*. 2006;17(8):989-1003.
9. Larsson SC, Wolk A. Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies. *The American journal of clinical nutrition*. 2007;86(3):556-65.
10. De Pergola G, Silvestris F. Obesity as a major risk factor for cancer. *Journal of obesity*. 2013;2013.
11. Louie SM, Roberts LS, Nomura DK. Mechanisms linking obesity and cancer. *Biochimica Et Biophysica Acta (BBA)-Molecular And Cell Biology Of Lipids*. 2013;1831(10):1499-508.
12. Chan D, Vieira A, Aune D, Bandera E, Greenwood D, McTiernan A, et al. Body mass index and survival in women with breast cancer—systematic literature review and meta-analysis of 82 follow-up studies. *Annals of Oncology*. 2014;25(10):1901-14.
13. Vitolins MZ, Kimmick GG, Case LD. BMI influences prognosis following surgery and adjuvant chemotherapy for lymph node-positive breast cancer. *The breast journal*. 2008;14(4):357-65.
14. Dignam JJ, Wieand K, Johnson KA, Raich P, Anderson SJ, Smokin C, et al. Effects of obesity and race on prognosis in lymph node-negative, estrogen receptor-negative breast cancer. *Breast cancer research and treatment*. 2006;97(3):245-54.
15. Chlebowski RT, Aiello E, McTiernan A. Weight loss in breast cancer patient management. *Journal of clinical oncology*. 2002;20(4):1128-43.
16. Ryu SY, Kim CB, Nam CM, Park JK, Kim KS, Park J, et al. Is body mass index the prognostic factor in breast cancer?: a meta-analysis. *Journal of Korean medical science*. 2001;16(5):610.
17. Greene F, Page D, Fleming I, Cancer AJCo. Cancer staging manual. American Joint Committee on Cancer (AJCC); Digestive System; Lippincott Raven Publishers: Philadelphia, PA, USA. 2002:113-24.
18. Organization WH. Tumors of the breast and female genital organs. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Breast and Female Genital Organs Lyon: International Agency for Research in Cancer. 2003.
19. Organization WH, Ageing WHO, Unit LC. WHO global report on falls prevention in older age: World Health Organization; 2008.
20. Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madarnas Y, et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. *Journal of clinical oncology*. 2002;20(1):42-51.
21. Group EHBCC. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. *Journal of the National Cancer Institute*. 2003;95(16):1218-26.
22. Berclaz G, Li S, Price Kn, Coates aS, Castiglione-Gertsch M, rudenstam CM, et al. Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience *ann Oncol*. 2004;15:875-84.
23. Kroenke CH, Chen WY, Rosner B, Holmes MD. Weight, weight gain, and survival after a breast cancer diagnosis. *Journal of clinical oncology*. 2005;23(7):1370-8.

24. Caan BJ, Kwan ML, Hartzell G, Castillo A, Slattery ML, Sternfeld B, et al. Pre-diagnosis body mass index, post-diagnosis weight change, and prognosis among women with early-stage breast cancer. *Cancer Causes & Control*. 2008;19(10):1319-28.
25. Majed B, Moreau T, Senouci K, Salmon RJ, Fourquet A, Asselain B. Is obesity an independent prognosis factor in woman breast cancer? *Breast cancer research and treatment*. 2008;111(2):329-42.
26. Ewertz M, Jensen M-B, Gunnarsdóttir KÁ, Højris I, Jakobsen EH, Nielsen D, et al. Effect of obesity on prognosis after early-stage breast cancer. *Journal of Clinical Oncology*. 2010;29(1):25-31.
27. Protani M, Coory M, Martin JH. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. *Breast cancer research and treatment*. 2010;123(3):627-35.
28. Ligibel JA, Goodwin PJ. NEW and RENEW: building the case for weight loss in breast cancer. *American Society of Clinical Oncology*; 2012.
29. Huang Z, Hankinson SE, Colditz GA, Stampfer MJ, Hunter DJ, Manson JE, et al. Dual effects of weight and weight gain on breast cancer risk. *Jama*. 1997;278(17):1407-11.
30. Lahmann PH, Hoffmann K, Allen N, Van Gils CH, Khaw KT, Tehard B, et al. Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer And Nutrition (EPIC). *International journal of cancer*. 2004;111(5):762-71.
31. Moon H-G, Han W, Noh D-Y. Underweight and breast cancer recurrence and death: a report from the Korean Breast Cancer Society. *Journal of Clinical Oncology*. 2009;27(35):5899-905.
32. Chen S, Chen C-M, Zhou Y, Zhou R-J, Yu K-D, Shao Z-M. Obesity or overweight is associated with worse pathological response to neoadjuvant chemotherapy among Chinese women with breast cancer. *PLoS One*. 2012;7(7):e41380.
33. Suzuki R, Saji S, Toi M. Impact of body mass index on breast cancer in accordance with the life-stage of women. *Frontiers in oncology*. 2012;2:123.
34. Mæhle BO, Tretli S. Pre-morbid body-mass-index in breast cancer: reversed effect on survival in hormone receptor negative patients. *Breast cancer research and treatment*. 1996;41(2):123-30.
35. Tretli S, Haldorsen T, Ottestad L. The effect of pre-morbid height and weight on the survival of breast cancer patients. *British journal of cancer*. 1990;62(2):299.
36. Senie RT, Rosen PP, Rhodes P, Lesser ML, Kinne DW. Obesity at diagnosis of breast carcinoma influences the duration of disease-free survival. *Annals of internal medicine*. 1992;116(1):26-32.
37. Katoh A, Watzlaf V, D'Amico F. An examination of obesity and breast cancer survival in postmenopausal women. *British journal of cancer*. 1994;70(5):928.
38. De Azambuja E, McCaskill-Stevens W, Francis P, Quinaux E, Crown JP, Vicente M, et al. The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial. *Breast cancer research and treatment*. 2010;119(1):145-53.
39. Bastarrachea J, Hortobagyi GN, Smith TL, Kau S-WC, Buzdar AU. Obesity as an adverse prognostic factor for patients receiving adjuvant chemotherapy for breast cancer. *Annals of internal medicine*. 1994;120(1):18-25.

40. Daling JR, Malone KE, Doody DR, Johnson LG, Gralow JR, Porter PL. Relation of body mass index to tumor markers and survival among young women with invasive ductal breast carcinoma. *Cancer*. 2001;92(4):720-9.

Table 1. Patient characteristics

	Total N = 629		BMI								P valu e
			Underweigh t N = 21		Normal Weight N= 227		Overweight N = 180		Obese N = 201		
	N	%	N	%	N	%	N	%	N	%	
Age (Years)											
Mean (SD)	51.1(11 .7)		46.5(13 .1)		50.4(12 .9)		49(10. 7)		52.8(10 .9)		
Median	50		45		49		48.5		50		

Tumor Stage											
Stage I	8	1.4	0	0	2	25	2	25	4	50	
Stage II											
Stage IIA	125	19.8	4	3.2	44	35.2	38	30.4	39	31.2	p = 0.732
Stage IIB	168	26.8	8	4.7	66	39.2	52	30.9	42	25.2	
Stage III											
Stage IIIA	222	35.2	8	3.6	72	32.5	63	28.4	79	35.5	p = 0.443
Stage IIIB	106	16.8	1	1	43	40.5	25	23.5	37	35	
Menopausal Status											
Premenopausal	298	47.3	12	4	120	40.2	94	31.6	72	24.2	p = 0.196
Postmenopausal	331	52.7	9	2.7	107	32.3	86	26	129	39	
Tumor grade											
G I	6	1	0	0	4	66.7	0	0	2	33.3	p = 0.486
G II	555	88.1	20	3.6	197	35.5	164	29.5	174	31.4	
G III	68	10.9	1	1.5	26	38.3	16	23.5	25	36.7	
Hormonal Status											
ER											
Positive	286	45.8	8	2.8	105	36.7	80	28	93	32.5	p = 0.941
Negative	126	19.9	1	2.4	44	34.9	36	27	45	35.7	
Unknown	217	34.3	12	5.5	78	37.3	64	30	63	27.2	
PR											
Positive	288	46	5	2.5	105	36.4	82	27.8	96	33.3	P = 0.877
Negative	122	19.3	4	3.4	40	35.2	32	27	46	34.4	
Unknown	219	34.7	12	5.5	82	37.4	66	30.1	59	27	

Fig 1. Overall Survival Of Breast Cancer Patients





Fig 2. Disease Free Survival Of Breast Cancer Patients



UNDER PEER RL